• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

长链非编码RNA FENDRR中的基因变异与肥厚型心肌病发生风险的关联

Association of the Genetic Variation in the Long Non-Coding RNA FENDRR with the Risk of Developing Hypertrophic Cardiomyopathy.

作者信息

Cuesta-Llavona Elías, Lorca Rebeca, Rolle Valeria, Alonso Belén, Iglesias Sara, Rodríguez-Reguero Julian, Duarte-Herrera Israel David, Pérez-Oliveira Sergio, Junco-Vicente Alejandro, Lago Claudia García, Coto Eliecer, Gómez Juan

机构信息

Hospital Universitario Central de Asturias (HUCA), 33011 Oviedo, Spain.

Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.

出版信息

Life (Basel). 2022 May 30;12(6):818. doi: 10.3390/life12060818.

DOI:10.3390/life12060818
PMID:35743849
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9225451/
Abstract

Background: In around 40−60% of Hypertrophic Cardiomyopathy (HCM) cases pathogenic variants are not identified. Our aim was to evaluate the possible association of lncRNAs with the risk of developing HCM. Methods: We sequenced 10 lncRNAs coding genes that have been associated with cardiovascular disease in a discovery cohort (238 HCM patients and 212 controls) by NGS, and genotyped rs74035787 G>A and rs1424019 A>G polymorphism in a validation cohort (962 HCM patients and 923 controls). Finally, we sequenced the FENDRR promoter by Sanger sequencing. Results: We observed by NGS that FENDRR rs39527, rs39529 and rs40384 polymorphisms were significantly associated with HCM in our cohort (p = 0.0284; OR: 0.24, 95%CI: 0.07−0.86). NGS results were confirmed by genotyping rs74035787 polymorphism (p = 0.001; OR:0.38, 95%CI: 0.21−0.66). Moreover, it is also associated when stratification by sex (p = 0.003; OR:0.20, 95%CI: 0.06−0.53), and age (≥50 years old p = 0.001, OR:0.33, 95%CI: 0.16−0.63) Moreover, the risk of HCM in the carriers of the GG genotype of the rs1424019 polymorphism was significantly higher than that of the AA/AG genotypes carriers in the elderly subjects (p = 0.045, OR:1.24, 95%CI: 1.01−1.53). On the other hand, we observed significant differences in the rs74035787 A/rs1424019 G haplotype frequency (p = 0.0035; OR: 0.20, 95%CI: 0.07−0.59). Conclusions: Our study suggested a significant association between FENDRR gene variants and HCM.

摘要

背景

在大约40%-60%的肥厚型心肌病(HCM)病例中,未发现致病变异。我们的目的是评估长链非编码RNA(lncRNAs)与发生HCM风险之间的可能关联。方法:我们通过二代测序(NGS)对发现队列(238例HCM患者和212例对照)中10个已与心血管疾病相关的lncRNAs编码基因进行测序,并在验证队列(962例HCM患者和923例对照)中对rs74035787 G>A和rs1424019 A>G多态性进行基因分型。最后,我们通过桑格测序对FENDRR启动子进行测序。结果:通过NGS我们观察到,在我们的队列中FENDRR rs39527、rs39529和rs40384多态性与HCM显著相关(p = 0.0284;OR:0.24,95%CI:0.07-0.86)。通过对rs74035787多态性进行基因分型证实了NGS结果(p = 0.001;OR:0.38,95%CI:0.21-0.66)。此外,按性别分层(p = 0.003;OR:0.20,95%CI:0.06-0.53)和年龄(≥50岁,p = 0.001,OR:0.33,95%CI:0.16-0.63)时也存在关联。此外,在老年受试者中,rs1424019多态性GG基因型携带者发生HCM的风险显著高于AA/AG基因型携带者(p = 0.045,OR:1.24,95%CI:1.01-1.53)。另一方面,我们观察到rs74035787 A/rs1424019 G单倍型频率存在显著差异(p = 0.0035;OR:0.20,95%CI:0.07-0.59)。结论:我们的研究表明FENDRR基因变异与HCM之间存在显著关联。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f190/9225451/148ef0f6dedc/life-12-00818-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f190/9225451/148ef0f6dedc/life-12-00818-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f190/9225451/148ef0f6dedc/life-12-00818-g001.jpg

相似文献

1
Association of the Genetic Variation in the Long Non-Coding RNA FENDRR with the Risk of Developing Hypertrophic Cardiomyopathy.长链非编码RNA FENDRR中的基因变异与肥厚型心肌病发生风险的关联
Life (Basel). 2022 May 30;12(6):818. doi: 10.3390/life12060818.
2
Prognostic predictive value of TLR4 polymorphisms in Han Chinese population with hypertrophic cardiomyopathy.TLR4 多态性对汉族肥厚型心肌病患者预后的预测价值。
Kaohsiung J Med Sci. 2018 Oct;34(10):569-575. doi: 10.1016/j.kjms.2018.05.004. Epub 2018 Jun 2.
3
Genetic variation at the long noncoding RNA H19 gene is associated with the risk of hypertrophic cardiomyopathy.长链非编码 RNA H19 基因的遗传变异与肥厚型心肌病的风险相关。
Epigenomics. 2018 Jul;10(7):865-873. doi: 10.2217/epi-2017-0175. Epub 2018 Jul 2.
4
Polymorphisms of angiotensin-converting enzyme 2 gene associated with magnitude of left ventricular hypertrophy in male patients with hypertrophic cardiomyopathy.血管紧张素转换酶2基因多态性与男性肥厚型心肌病患者左心室肥厚程度相关。
Chin Med J (Engl). 2008 Jan 5;121(1):27-31.
5
Atrial natriuretic peptide gene polymorphism is not associated with hypertrophic cardiomyopathy.心房利钠肽基因多态性与肥厚型心肌病无关。
Chin Med J (Engl). 2010 Jan 20;123(2):188-92.
6
Mutation analysis of the main hypertrophic cardiomyopathy genes using multiplex amplification and semiconductor next-generation sequencing.使用多重扩增和半导体下一代测序技术对主要肥厚型心肌病基因进行突变分析。
Circ J. 2014;78(12):2963-71. doi: 10.1253/circj.cj-14-0628. Epub 2014 Oct 22.
7
First identification of homozygous truncating CSRP3 variants in two unrelated cases with hypertrophic cardiomyopathy.首次在两例无关联的肥厚型心肌病患者中鉴定出 CSRP3 基因纯合截断变异。
Gene. 2018 Nov 15;676:110-116. doi: 10.1016/j.gene.2018.07.036. Epub 2018 Jul 17.
8
Whole MYBPC3 NGS sequencing as a molecular strategy to improve the efficiency of molecular diagnosis of patients with hypertrophic cardiomyopathy.全 MYBPC3 NGS 测序作为提高肥厚型心肌病患者分子诊断效率的分子策略。
Hum Mutat. 2020 Feb;41(2):465-475. doi: 10.1002/humu.23944. Epub 2019 Nov 15.
9
The utility of the Mayo Score for predicting the yield of genetic testing in patients with hypertrophic cardiomyopathy.梅奥评分在预测肥厚型心肌病患者基因检测结果方面的效用。
Arch Med Sci. 2019 May;15(3):641-649. doi: 10.5114/aoms.2018.78767. Epub 2018 Oct 8.
10
Associations Between Female Sex, Sarcomere Variants, and Clinical Outcomes in Hypertrophic Cardiomyopathy.女性性别、肌节变体与肥厚型心肌病临床结局的相关性。
Circ Genom Precis Med. 2021 Feb;14(1):e003062. doi: 10.1161/CIRCGEN.120.003062. Epub 2020 Dec 7.

引用本文的文献

1
Unlocking the therapeutic potential of lncRNA FENDRR in DCM: novel targets and insights via the miR-296-5p/HMGA1 axis.解锁长链非编码RNA FENDRR在扩张型心肌病中的治疗潜力:通过miR-296-5p/HMGA1轴的新靶点及见解
J Cardiothorac Surg. 2025 May 31;20(1):254. doi: 10.1186/s13019-025-03477-9.
2
Transcriptomic Analyses and Experimental Validation Identified Immune-Related lncRNA-mRNA Pair - Regulating the Progression of Hypertrophic Cardiomyopathy.转录组分析与实验验证确定了免疫相关lncRNA-mRNA对——调控肥厚型心肌病的进展
Int J Mol Sci. 2024 Feb 29;25(5):2816. doi: 10.3390/ijms25052816.
3
A Small De Novo CNV Deletion of the Paternal Copy of , Leaving lncRNA Intact, Provides Insight into Their Bidirectional Promoter Region.

本文引用的文献

1
Sex Differences in Hypertrophic Cardiomyopathy: Interaction With Genetics and Environment.肥厚型心肌病的性别差异:与遗传和环境的相互作用。
Curr Heart Fail Rep. 2021 Oct;18(5):264-273. doi: 10.1007/s11897-021-00526-x. Epub 2021 Sep 3.
2
The Therapeutic Value and Molecular Mechanisms of lncRNA FENDRR in Human Cancer.lncRNA FENDRR 在人类癌症中的治疗价值和分子机制。
Curr Pharm Des. 2021;27(39):4100-4106. doi: 10.2174/1381612827666210820094702.
3
Long non-coding RNA Pvt1 modulates the pathological cardiac hypertrophy via miR-196b-mediated OSMR regulation.
一个涉及父本拷贝的小的从头发生的拷贝数变异缺失,lncRNA保持完整,为其双向启动子区域提供了见解。
Noncoding RNA. 2023 Oct 9;9(5):61. doi: 10.3390/ncrna9050061.
4
LncRNA Fendrr: involvement in the protective role of nucleolin against HO-induced injury in cardiomyocytes.长链非编码 RNA Fendrr:在核仁蛋白对抗 HO 诱导的心肌细胞损伤中的保护作用中的参与。
Redox Rep. 2023 Dec;28(1):2168626. doi: 10.1080/13510002.2023.2168626.
长链非编码RNA Pvt1通过miR-196b介导的OSMR调控来调节病理性心脏肥大。
Cell Signal. 2021 Oct;86:110077. doi: 10.1016/j.cellsig.2021.110077. Epub 2021 Jul 8.
4
FENDRR: A pivotal, cancer-related, long non-coding RNA.FENDRR:一个关键的、与癌症相关的长非编码 RNA。
Biomed Pharmacother. 2021 May;137:111390. doi: 10.1016/j.biopha.2021.111390. Epub 2021 Feb 16.
5
Long Non-Coding RNA : Gene Structure, Expression, and Biological Relevance.长非编码 RNA:基因结构、表达及生物学相关性。
Genes (Basel). 2021 Jan 27;12(2):177. doi: 10.3390/genes12020177.
6
FENDRR Sponges miR-424-5p to Inhibit Cell Proliferation, Migration and Invasion in Colorectal Cancer.FENDRR 海绵 miR-424-5p 抑制结直肠癌细胞增殖、迁移和侵袭。
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820980102. doi: 10.1177/1533033820980102.
7
Prevalence, functional characteristics, and clinical significance of right ventricular involvement in patients with hypertrophic cardiomyopathy.肥厚型心肌病患者右心室受累的患病率、功能特征及临床意义。
Sci Rep. 2020 Dec 14;10(1):21908. doi: 10.1038/s41598-020-78945-4.
8
Influence of Gender on Clinical Characteristics and Outcomes in Chinese Patients With Hypertrophic Cardiomyopathy.性别对中国肥厚型心肌病患者临床特征和结局的影响。
Am J Med Sci. 2020 Nov;360(5):517-524. doi: 10.1016/j.amjms.2020.05.017. Epub 2020 May 20.
9
LncRNA Fendrr inhibits hypoxia/reoxygenation-induced cardiomyocyte apoptosis by downregulating p53 expression.长链非编码 RNA Fendrr 通过下调 p53 表达抑制低氧/复氧诱导的心肌细胞凋亡。
J Pharm Pharmacol. 2020 Sep;72(9):1211-1220. doi: 10.1111/jphp.13298. Epub 2020 Jun 15.
10
Fendrr involves in the pathogenesis of cardiac fibrosis via regulating miR-106b/SMAD3 axis.Fendrr 通过调节 miR-106b/SMAD3 轴参与心脏纤维化的发病机制。
Biochem Biophys Res Commun. 2020 Mar 26;524(1):169-177. doi: 10.1016/j.bbrc.2020.01.062. Epub 2020 Jan 23.